Targeting GCN5-mediated ERK lactylation: A promising drug development frontier in cancer therapy
• GCN5 mediates ERK K231 lactylation linking glycolysis to oncogenic MAPK signaling. • Targeting GCN5 lactylation offers a strategy to overcome resistance to MEK or ERK inhibitors. • Modulating lactylation reshapes the tumor immune microenvironment and enhances T cell function. • Inhibiting site-specific lactylation is a precise strategy for glycolytic RAS ERK driven cancers.
Authors
- Yen‐Dun Tony Tzeng (ORCID: https://orcid.org/0000-0003-1502-0840)
- Chia‐Jung Li (ORCID: https://orcid.org/0000-0002-3773-9015)
- An-Jen Chiang
Institutions
- National Sun Yat-sen University (TW)
- Kaohsiung Veterans General Hospital (TW)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1016/j.biopha.2026.119128
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00